In the USA, two New Drug Applications (NDA) for crinecerfont have been accepted by the US regulator, and will be considered under the Priority Review scheme. 1 July 2024
US gene therapy company Regenxbio has announced that co-founder Kenneth Mills is to step down as president and chief executive following 15 years of leadership 12 June 2024
Calico Life Sciences, a biotech company specializing in aging and age-related diseases, has had its candidate fosigotifator accepted into the US Food and Drug A 10 June 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.